Trial Profile
A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin detemir
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 26 Apr 2012 Actual end date (1 Feb 2010) added as reported by ClinicalTrials.gov.
- 26 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2009 New trial record